All In Biotech

Drug Trial Radar · NCT05823246

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

A Phase II Study to Evaluate the Efficacy and Safety of QLF31907 Injection in Patients With Advanced Melanoma and Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: May 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

66

Planned (sponsor's estimate)

Start

Apr 24, 2023

Primary completion

Oct 2023

Study completion Jul 2024

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.

Conditions

  • Melanoma
  • Urothelial Carcinoma

Interventions

  • QLF31907Drug

    Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (part 1)Dose-limiting toxicity(DLT)Time frame: 28days
  2. (part 2) Objective response rate(ORR)Time frame: up to 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • West China Hospital

    Chengdu, Sichuan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.